ASCO 2026: Roche's Giredestrant Flops in First-Line Metastatic Breast Cancer but Secures FDA Priority Review in Adjuvant Setting

ASCO 2026: Roche's Giredestrant Flops in First-Line Metastatic Breast Cancer but Secures FDA Priority Review in Adjuvant Setting

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Roche detailed the long-awaited full results from its Phase 3 persevERA BC trial evaluating giredestrant—its investigational oral selective estrogen receptor degrader (SERD).

While the trial failed to meet its primary endpoint in first-line metastatic breast cancer, Roche's leadership remains highly confident in giredestrant's multi-billion-dollar blockbuster potential, buoyed by a parallel regulatory path in the early-stage adjuvant setting.¹

The First-Line persevERA Flop

The Phase 3 persevERA BC trial (NCT04546009) evaluated first-line giredestrant in combination with Pfizer’s CDK4/6 inhibitor Ibrance (palbociclib) against Novartis’ standard aromatase inhibitor Femara (letrozole) plus Ibrance in 1,034 patients with hormone receptor-positive (HR+), HER2-negative locally advanced or metastatic breast cancer.

The study did not achieve statistical significance:

• Progression-Free Survival (PFS): The giredestrant regimen achieved a median PFS of 33.1 months, compared to 28.2 months in the control letrozole arm. While this represents a numerical improvement of 4.9 months, the investigator-assessed hazard ratio (HR) was 0.89 (an 11% relative risk reduction), which failed to reach statistical significance.
• Overall Survival (OS): Giredestrant showed no survival advantage, with an immature hazard ratio of 1.03, indicating a marginally higher risk of death for the giredestrant group. The three-year OS rates were identical at 74.1% for both arms.
• CDK4/6 Blunting Effect: Roche researchers hypothesized that the extreme potency of the CDK4/6 inhibitor (palbociclib) may have masked or "blunted" the added benefit of endocrine manipulation with giredestrant early in the treatment course.
• Safety Profile: Adverse events (AEs) were generally comparable, though serious AEs were higher in the giredestrant arm (23.9% vs. 18.8% in the control arm).

Pivot to the Lucrative Adjuvant Market

Despite the metastatic setback, the FDA accepted Roche’s Biologics License Application (BLA) for giredestrant in HR+ early-stage breast cancer for Priority Review, setting a target PDUFA action date of November 30, 2026.

This filing is supported by the positive Phase 3 lidERA trial, which evaluated giredestrant as a monotherapy in the adjuvant (post-surgery) setting. In early-stage breast cancer, giredestrant demonstrated a 30% reduction in the risk of invasive disease recurrence (iDFS) compared to standard endocrine therapy.

New subgroup data presented at ASCO 2026 from the lidERA trial further confirmed that giredestrant's benefit holds regardless of menopausal status, reducing recurrence risk by 35% in pre-menopausal patients and 26% in post-menopausal patients.

Roche's strategic focus is heavily weighted toward the adjuvant market, which represents three times more drug-treated patients than the first-line metastatic setting and requires a much longer five-year treatment duration. To cement its position, Roche is currently designing a new adjuvant trial combining giredestrant with CDK4/6 inhibitors and is conducting safety substudies pairing giredestrant with Eli Lilly's Verzenio (abemaciclib) and Novartis' Kisqali (ribociclib).

Verbatim Quotes

• Dr. Stefan Frings (Roche Deputy Chief Medical Officer): "What we still see is a quite attractive separation of the curve […] You will clearly see there’s a treatment effect... This convinces us, because in the adjuvant setting, we treat for five years, and if we move a few percentage points upwards, you would have already a positive treatment effect in the adjuvant setting."
• Dr. Stefan Frings (Roche Deputy Chief Medical Officer): "The reason why this may not have worked is that certainly CDK4/6 [inhibitors] are very potent agents... and that you don’t see early on what is really an effect of an endocrine manipulation. A dead cell is dead, and you can’t kill it better when it’s already dead."
• Teresa Graham (Roche Pharmaceuticals CEO): "The adjuvant setting is a much larger market with three times more drug-treated patients than in first-line metastatic and a much longer treatment duration [of] around five years.²" (Quoted in Fierce Biotech via April investor call).